Patients with very early axial spondyloarthritis (axSpA) who started a first TNF inhibitor within 1 year of the onset of back pain did not have better 1-year clinical outcomes or longer drug retention ...

Please provide your email address to receive an email when new articles are posted on . Switching from a TNF inhibitor to upadacitinib was superior to cycling TNF inhibitors. Upadacitinib outcomes ...

Patients with axial spondyloarthritis (axSpA) treated with tumor necrosis factor (TNF) inhibitors were at significantly lower risk for hip and spine fractures compared with those receiving only ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with axial SpA treated with TNF inhibitors had ...

Children with nonsystemic juvenile idiopathic arthritis who initiated TNF inhibitors when aged 2 years or less showed significant and sustained improvements in disease activity. Early initiation of ...

Experts offer treatment tips for patients with axial spondyloarthritis who also have inflammatory bowel disease.

The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry. The ...

Drug retention was similar with second-line IL-17 inhibitors vs TNF inhibitors in patients with axial spondyloarthritis who discontinued their initial TNF inhibitor, though IL-17 inhibitors showed ...

Forward Therapeutics, Inc (“Forward” or “the Company”), a clinical-stage biotechnology company developing oral small molecule ...

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease. A new study published recently in the journal Gut shows children with Crohn's who ...

ORLANDO -- Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase (JAK) inhibitors than with tumor necrosis factor (TNF) inhibitors, ...